Table IV.
Response and Duration
N (%) | Time to Response Median (range) |
|
---|---|---|
Complete Response (ALL) | 1 (6%) | 53 days |
Partial Response (AML) | 1 (6%) | 77 days |
Stable Disease (NHL, AML) | 2 (12%) | 68.5 days (52–85 days) |
Disease Progression | ||
No response | 7 (41%) | |
Unevaluable* | 2 (12%) | |
4 (24%) |
Defined as not receiving all 12 doses of drug